(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.24%) $83.77
(-2.87%) $1.591
(-0.06%) $2 341.10
(0.01%) $27.36
(0.85%) $928.30
(0.05%) $0.932
(0.02%) $10.95
(0.05%) $0.800
(0.02%) $92.18
Live Chart Being Loaded With Signals
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions...
Stats | |
---|---|
Today's Volume | 210 358 |
Average Volume | 264 087 |
Market Cap | 210.57M |
EPS | $-0.310 ( 2024-03-19 ) |
Next earnings date | ( $-0.270 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.91 |
ATR14 | $0.00600 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Schmid John P. | Buy | 17 809 | Common Stock |
2024-03-22 | Schmid John P. | Buy | 9 156 | Common Stock |
2024-03-25 | Berger Heather A. | Buy | 1 300 | Common Stock |
2024-03-13 | Kim Jae B. | Sell | 0 | Common Stock |
2024-03-13 | Kim Jae B. | Sell | 315 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
76.49 |
Last 96 transactions |
Buy: 40 774 561 | Sell: 39 424 073 |
Volume Correlation
Design Therapeutics, Inc. Correlation
10 Most Positive Correlations | |
---|---|
GRNV | 0.943 |
MTSL | 0.933 |
ENOB | 0.931 |
TFFP | 0.927 |
KBSF | 0.924 |
LYEL | 0.922 |
RPID | 0.912 |
PEV | 0.911 |
ZI | 0.91 |
SVAC | 0.908 |
10 Most Negative Correlations | |
---|---|
AGFS | -0.948 |
HEES | -0.94 |
NECB | -0.94 |
LYTS | -0.937 |
PTMN | -0.934 |
LWAC | -0.929 |
HOFT | -0.928 |
IVAC | -0.927 |
LRFC | -0.92 |
ISDX | -0.913 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Design Therapeutics, Inc. Correlation - Currency/Commodity
Design Therapeutics, Inc. Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.00120 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-137 000 (0.00 %) |
EPS: | $-0.280 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-143 000 (0.00 %) |
EPS: | $-0.360 |
Q1 | 2023 |
Revenue: | $0 |
Gross Profit: | $-139 000 (0.00 %) |
EPS: | $-0.300 |
Financial Reports:
No articles found.
Design Therapeutics, Inc.
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators